Compare Citius Pharmaceuticals Inc (CTXR) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Verisign, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Verisign, Inc. trades at $288.99 (market cap $26.00B). The key difference: Verisign, Inc. is far larger — about 1299.4× Citius Pharmaceuticals Inc's market cap, and Verisign, Inc. pays a 1.13% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | VRSN | |
|---|---|---|
Market Cap | $20.01M | $26.00B |
Sector | Health | Technology |
52-Week High | $1.82 | $310.00 |
52-Week Low | $0.48 | $211.49 |
Enterprise Value | $16.23M | $27.31B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.
VeriSign (VRSN) trades at $282.94, down 3.55% over the past day, with a mixed earnings history including a recent Q2 2026 EPS miss. The stock shows a bullish technical trend with strong moving averages, while fundamentals highlight robust profitability with a net income margin near 50% and revenue growth to $1.66B in 2025. Recent news emphasizes record domain registrations and the delegation of the .web domain, supporting growth outlook.
The outlook remains positive with a consensus price target of $320, reflecting 13% upside, driven by AI-fueled domain demand and pricing power. Risks include contract renewals and high debt levels, but analyst sentiment is bullish with 60% buy ratings. The stock presents a growth opportunity with manageable execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
